Loading company…
PAQ Therapeutics develops small-molecule therapies using autophagosome-tethering compound technology.
Founded in 2020, PAQ Therapeutics develops therapies using autophagosome-tethering compounds to target disease-associated cellular components, including proteins, mitochondria, lipids, and pathogens. Its co-founders are Nan Ji, Boxun Lu, and Huaixiang Hao. In January 2026, it raised USD 38 million in Series B+ funding led by Sherpa Healthcare Partners, with Huagai Capital, MSA Capital, MRL Ventures Fund, Nest.Bio Labs, and MPC participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in